MBX Biosciences (MBX) Current Assets (2023 - 2026)

MBX Biosciences has disclosed Current Assets across 4 years of filings, most recently posting $448.5 million for Q1 2026.

• Current Assets for Q1 2026 came in at $448.5 million, up 83.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $448.5 million (up 83.62% YoY), and the FY2025 annual result was $381.5 million, up 42.75% from the prior year.
• Current Assets came in at $448.5 million for Q1 2026 at MBX Biosciences, up from $381.5 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $448.5 million in Q1 2026 to a low of $83.5 million in Q4 2023.
• The 4-year median for Current Assets is $274.2 million (2024), against an average of $291.6 million.
• Across the five-year window, Current Assets jumped 220.24% in 2024 and surged 41.37% in 2025, its largest moves.
• MBX Biosciences' Current Assets stood at $83.5 million in 2023, then surged by 220.24% to $267.3 million in 2024, then surged by 42.75% to $381.5 million in 2025, then grew by 17.56% to $448.5 million in 2026.
• The last three Current Assets figures came in at $448.5 million (Q1 2026), $381.5 million (Q4 2025), and $397.5 million (Q3 2025), per Business Quant data.